Labor PainNCT06819579
Exploring the Optimal Concentration of Lidocaine Test Dose for Labor Analgesia
A study testing 1.5% Lidocaine, 1.0% Lidocaine and 0.5% Lidocaine in people with Labor Pain, run by The Second Affiliated Hospital of Chongqing Medical University at 1 site in China.
Trial summary
This study aims to compare the analgesia effects and side effects of different concentrations of test dose lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinic al practice of labor analgesia. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Labor Pain
- What is being tested?
- 1.5% Lidocaine, 1.0% Lidocaine and 0.5% Lidocaine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 99 participants
- Where
- 1 siteChina
- Study dates
- 10 Mar 2025to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Singleton primipara
- Aged 20-40 years
- Pre-assessed as eligible for vaginal delivery
- Height between 155-170 cm, BMI between 18.5-35 kg/m²
- Cervical dilation between 2-6 cm
- No significant history of cardiopulmonary disease
Show all 9Show fewer
- No history of surgical trauma
- American Society of Anesthesiologists (ASA) Grades I-III
- Patients are willing to participate and be able to understand and sign an informed consent form
Who cannot join
- Contraindications for spinal anesthesia, such as coagulopathy or ongoing anticoagulant therapy, infection at the puncture site, bacteremia, epidural abscess, increased intracranial pressure, severe hypovolemia
- Physical or mental disabilities, such as scoliosis and depression, alcohol or drug abuse
- Major organ diseases, such as hyperthyroidism, cardiopulmonary diseases, diabetes treated with insulin, and neuromuscular diseases
- Numerical Pain Rating Scale (NPRS) < 5
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country.
China1 site
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000
About this study
This study aims to compare the analgesia effects and side effects of different concentrations of test dose lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinic al practice of labor analgesia.
Read the detailed description
Epidural analgesia is the most effective and widely used analgesic method for relieving labor pain in clinical practice. However, inadvertent insertion of an epidural catheter into a blood vessel or subarachnoid space may result in local anesthesia or total spinal anesthesia, which can be life-threatening. Therefore, a low-concentration, low-volume dose of local anesthetic is usually injected as a test dose before injecting a large dose of local anesthetic through the epidural catheter to ensure that the catheter is within the epidural space. At present, the guidelines recommend 3 ml of 1.5% lidocaine as the test dose, but in clinical practice and the study of Chen et al., it was found that the test dose of 1.5% lidocaine 3ml still has a high incidence of lower limb motor block of 57.1%, which affects maternal activity and labor progression. In addition, Liu Henry et al. found that the incidence of 0.5% lidocaine 10 ml test dose-induced motor block was 0%, and the analgesic effect could be quickly achieved. Therefore, it is uncertain which concentration of lidocaine has the fastest onset of analgesia and the fewest side effects in labor analgesia. Therefore, this study aims to compare the effects of different concentrations of lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinical practice of labor analgesia.
- Conditions
- Labor Pain
- Being tested
- 1.5% Lidocaine, 1.0% Lidocaine, 0.5% Lidocaine
- Medical subject headings
- Labor Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
1.5% LidocaineDrug
Also called Lidocaine
After successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose
1.0% LidocaineDrug
After successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose
0.5% LidocaineDrug
After successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose
| Study group | Role | What they receive |
|---|---|---|
| 1.5% Lidocaine | Active comparator | After successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose Receives: Drug: 1.5% Lidocaine |
| 1.0% Lidocaine | Experimental | After successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose Receives: Drug: 1.0% Lidocaine |
| 0.5% Lidocaine | Experimental | After successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose Receives: Drug: 0.5% Lidocaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of motor block
Bromage Scores were used to grade movement block: I free movement of legs and feet, II free movement of feet with only bent knees, III free movement of feet without bending knees, IV no movement of legs and feet, with scores of II, III and IV considered as movement block.
Measured: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Secondary outcomes (13)
Pain scores
Pain scores is assessed by the Numerical Pain Rating Scale (NPRS, where 0 means no pain and 10 means no pain tolerance)
Measured: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Time of analgesia onset
Pain scores is assessed by the Numerical Pain Rating Scale (NPRS, where 0 means no pain and 10 means no pain tolerance). Analgesia is considered effective when NPRS is ≤3 or NPRS is reduced by ≥ 50% of the baseline value.
Measured: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Sensory block level
Midabdominal line acupuncture was used to assess the sensory block level
Measured: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Incidence of complications related to labor analgesia
Ask the patient if they have discomfort such as leg warmth, leg numbness, trembling, itching, headache, tinnitus, etc.
Measured: 30 minutes after lidocaine administration
frequency and intensity of uterine contractions
A contraction monitor is used to monitor the intensity and frequency of contractions
Measured: 30 minutes after lidocaine administration
Maternal blood pressure
Automated monitoring with an ECG monitor
Measured: 5,10,15,20,25,30 minutes after lidocaine administration
Maternal heart rate
Automated monitoring with an ECG monitor
Measured: 5,10,15,20,25,30 minutes after lidocaine administration
Pulse oximetry (SPO2)
Automated monitoring with an ECG monitor
Measured: 5,10,15,20,25,30 minutes after lidocaine administration
fetal heart rate
Automatically monitored using a fetal heart rate monitor
Measured: 5,10,15,20,25,30 minutes after lidocaine administration
Patient satisfaction score
Numerical rating scale was used to score (0, completely dissatisfied; 1. Neutral; 2, satisfaction; 3, completely satisfied)
Measured: 30 minutes after lidocaine administration
First stage of labor
The first stage of labor begins when labor starts and ends with full cervical dilation to 10 centimeters.
Measured: From enrollment to 1 minute after the baby comes out.
Second stage of labor
The time from the cervix dilated to 10 centimeters to the baby comes out.
Measured: From enrollment to 1 minute after the baby comes out.
neonatal Apgar score
The Apgar score is to evaluate the presence or absence of neonatal asphyxia and the severity of asphyxia from five aspects: Appearance, Pulse, Grimace, Activity and Respiration after birth, with each item being 0~2 points and a full score of 10 points.
Measured: 1, 5, and 10 minutes after baby comes out.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2025
- Study start10 Mar 2025
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Labor PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 99 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bing Chen, Ph.D, The Second Affiliated Hospital of Chongqing Medical University
- Investigators
- Bing Chen, Principal investigator, The Second Affiliated Hospital of Chongqing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06819579
- Sponsor's protocol ID
- 2024.276
- Status last verified
- Feb 2025
- First submitted
- 24 Jan 2025
- Last updated
- 2 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data (IPD) will be available with the responding author when required.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Optimal Concentration of Lidocaine Test Dose for Labor Analgesia
- ClinicalTrials.gov ID
- NCT06819579
- Acronym / sponsor ID
- 2024.276
- Conditions
- Labor Pain
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 99 participants (estimated)
- Lead sponsor
- The Second Affiliated Hospital of Chongqing Medical UniversityUniversity, hospital or other
- Study start
- 10 Mar 2025 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 11 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the analgesia effects and side effects of different concentrations of test dose lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinic al practice of labor analgesia.
Detailed description
Epidural analgesia is the most effective and widely used analgesic method for relieving labor pain in clinical practice. However, inadvertent insertion of an epidural catheter into a blood vessel or subarachnoid space may result in local anesthesia or total spinal anesthesia, which can be life-threatening. Therefore, a low-concentration, low-volume dose of local anesthetic is usually injected as a test dose before injecting a large dose of local anesthetic through the epidural catheter to ensure that the catheter is within the epidural space. At present, the guidelines recommend 3 ml of 1.5% lidocaine as the test dose, but in clinical practice and the study of Chen et al., it was found that the test dose of 1.5% lidocaine 3ml still has a high incidence of lower limb motor block of 57.1%, which affects maternal activity and labor progression. In addition, Liu Henry et al. found that the incidence of 0.5% lidocaine 10 ml test dose-induced motor block was 0%, and the analgesic effect could be quickly achieved. Therefore, it is uncertain which concentration of lidocaine has the fastest onset of analgesia and the fewest side effects in labor analgesia. Therefore, this study aims to compare the effects of different concentrations of lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinical practice of labor analgesia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1.5% Lidocaine | Active comparator | Drug: 1.5% LidocaineAfter successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose |
| 1.0% Lidocaine | Experimental | Drug: 1.0% LidocaineAfter successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose |
| 0.5% Lidocaine | Experimental | Drug: 0.5% LidocaineAfter successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Singleton primipara
- Aged 20-40 years
- Pre-assessed as eligible for vaginal delivery
- Height between 155-170 cm, BMI between 18.5-35 kg/m²
- Cervical dilation between 2-6 cm
Key exclusion criteria (5 listed)
- Contraindications for spinal anesthesia, such as coagulopathy or ongoing anticoagulant therapy, infection at the puncture site, bacteremia, epidural abscess, increased intracranial pressure, severe hypovolemia
- Physical or mental disabilities, such as scoliosis and depression, alcohol or drug abuse
- Major organ diseases, such as hyperthyroidism, cardiopulmonary diseases, diabetes treated with insulin, and neuromuscular diseases
- Numerical Pain Rating Scale (NPRS) < 5
- Refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 1.5% LidocaineAlso: LidocaineAfter successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose | Drug | 1.5% Lidocaine |
| 1.0% LidocaineAfter successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose | Drug | 1.0% Lidocaine |
| 0.5% LidocaineAfter successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose | Drug | 0.5% Lidocaine |
Primary outcome
The incidence of motor block
Time frame: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Bromage Scores were used to grade movement block: I free movement of legs and feet, II free movement of feet with only bent knees, III free movement of feet without bending knees, IV no movement of legs and feet, with scores of II, III and IV considered as movement block.
13 secondary outcomes
Pain scores
Time frame: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Time of analgesia onset
Time frame: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Sensory block level
Time frame: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration
Incidence of complications related to labor analgesia
Time frame: 30 minutes after lidocaine administration
frequency and intensity of uterine contractions
Time frame: 30 minutes after lidocaine administration
Maternal blood pressure
Time frame: 5,10,15,20,25,30 minutes after lidocaine administration
Maternal heart rate
Time frame: 5,10,15,20,25,30 minutes after lidocaine administration
Pulse oximetry (SPO2)
Time frame: 5,10,15,20,25,30 minutes after lidocaine administration
fetal heart rate
Time frame: 5,10,15,20,25,30 minutes after lidocaine administration
Patient satisfaction score
Time frame: 30 minutes after lidocaine administration
First stage of labor
Time frame: From enrollment to 1 minute after the baby comes out.
Second stage of labor
Time frame: From enrollment to 1 minute after the baby comes out.
neonatal Apgar score
Time frame: 1, 5, and 10 minutes after baby comes out.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2025.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) will be available with the responding author when required.
Related trials for Labor Pain
Recruiting
The Effect Of Partner-Assısted Rebozo Technıque On Labor Paın And Satısfactıon In Prımary Pregnant Women
Labor Pains
RecruitingPhase 4
Analgesic Efficacy and Obstetric Effects of Tramadol, Paracetamol and Placebo in Active Labor
Labor Pain
Not yet recruiting
Pre-Examination Reflexology for Anxiety and Pain During Pelvic Examination
Anxiety
Recruiting
Pain Neuroscience-Based Education for Labor Pain in Pregnant Women
Labor Pain and Anxiety
Recruiting
The Effect of Breast Milk, 10% and 20% Dextrose on Pain and Physiological Variables During Heel Puncture in Infants
Newborn Care, Pain Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bing Chen principal investigator
The Second Affiliated Hospital of Chongqing Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 1.5% Lidocaine, 1.0% Lidocaine and 0.5% Lidocaine in people with Labor Pain, run by The Second Affiliated Hospital of Chongqing Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of motor block (time frame: 3,5,7,9,11,13,15,20,25,30 minutes after lidocaine administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2025.